Q4 2026 Blue Jet Healthcare Ltd Earnings Call Transcript
Key Points
- Blue Jet Healthcare Ltd (NSE:BLUEJET) reported a 22% increase in Q4 revenue on a quarter-over-quarter basis, driven by strong performance in the Contrast Media segment.
- The company has commenced its Vizag greenfield expansion project, which is expected to be a significant long-term growth platform.
- Blue Jet Healthcare Ltd is strengthening its R&D capabilities with a new center in Hyderabad, focusing on innovative chemistry platforms.
- The company is debt-free and ended FY26 with liquid financial assets of INR400 crores, indicating strong financial health.
- The PI segment is showing signs of recovery with improved order visibility and shipment trends, suggesting potential growth in FY27.
- Overall revenue for FY26 declined by 8% compared to FY25, indicating challenges in some business segments.
- The PI/API category saw a significant decline of 35% in revenue for FY26, primarily due to customer destocking.
- The artificial sweeteners segment faced pricing pressure from imports, leading to a 2% decline in revenue compared to FY25.
- EBITDA margin decreased to 31% in FY26 from 37% in FY25, impacted by lower volumes in the PI/API category.
- Logistics costs are expected to increase in FY27, which could impact overall profitability.
Good afternoon, and a warm welcome, everyone, to Q4 and FY26 Earnings Call of Blue Jet Healthcare Limited. Please note, the investor presentation and the financial results are available on the company's website and the stock exchanges. Also, anything said on this call which reflects our future outlook or which could be constituted as a forward-looking statement must be revised in conjunction with the risks that the company faces.
The conference call is being recorded, and the transcript along with the audio of the same will be made available on the website of the company as well as on the exchange. Please also note that the audio of the conference call is the copyright material of Blue Jet Healthcare Limited and cannot be copied, rebroadcasted or attributed in the press or media without specific and written consent of the company.
From the management, we have with us Mr. Shiven Arora, Managing Director; Mr. V.K. Singh, Chief Operating Officer; Mr. Ganesh Karuppannan, Chief Financial Officer; Mr. Sanjay Sinha, Deputy Chief Financial Officer. I would now like to hand the call over to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
